Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report
Authors:
Open Access
- 7 March 2020
- journal article
- research article
- Published by Elsevier in JTO Clinical and Research Reports
- Vol. 1 (2) , 100023
Abstract
No abstract availableKeywords
Funding Information
- Novartis
- Merck Sharp and Dohme United Kingdom
- Amgen
- Roche
- Astex Pharmaceuticals
- Bristol-Myers Squibb
- Sanofi
- Agios Pharmaceuticals
- Eli Lilly and Company
- Spectrum Pharmaceuticals
- Janssen Pharmaceutica
- Merck
- Merck KGaA
- AstraZeneca (17209098.7)
- Meso Scale Diagnostics
- Servier
- Bayer
- Boehringer Ingelheim
- Ipsen
- Genentech
- Takeda Pharmaceutical Company
- Johnson and Johnson
- GlaxoSmithKline España
- Celgene
- Daiichi-Sankyo
- Astellas Pharma US
- AbbVie
- MedImmune
- Pfizer
This publication has 15 references indexed in Scilit:
- Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitorsCancer Management and Research, 2019
- Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung CancersJournal of Thoracic Oncology, 2019
- Assessment of Resistance Mechanisms and Clinical Implications in Patients WithEGFRT790M–Positive Lung Cancer and Acquired Resistance to OsimertinibJAMA Oncology, 2018
- Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 studyAnnals of Oncology, 2018
- Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?Nature Reviews Clinical Oncology, 2018
- Beyond EGFR and ALK: targeting rare mutations in advanced non-small cell lung cancerAnnals of Translational Medicine, 2018
- Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterationsGenome Medicine, 2018
- OncoKB: A Precision Oncology Knowledge BaseJCO Precision Oncology, 2017
- High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 TrialCancer Discovery, 2017
- Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR -mutated NSCLC patients who had progressed on first- or second-generation EGFR TKILung Cancer, 2015